Protocol Ledger

NCT05153499 · Phase III · TERMINATED

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

Interventional Phase III clinical trial protocol NCT05153499 sponsored by Finch Research and Development in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-15 Enrollment: 19 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05153499
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)19 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05153499
Protocol FieldVerified Registry Value
NCT IdentifierNCT05153499
Consolidated Lead SponsorFinch Research and Development
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment19 participants (ACTUAL)
Registered Start Date2021-11-15
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI